
==== Front
BMJ Open
BMJ Open
bmjopen
bmjopen
BMJ Open
2044-6055 BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR 

bmjopen-2019-030501corr1
10.1136/bmjopen-2019-030501corr1
Correction
1506
Correction: Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial
2020 
9 3 2020 
9 3 2020 
10 3 e030501corr1© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2020http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.special-featureunlockedaccess-typefree
==== Body
Zhuang Q, Tao L, Lin J, et al. Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial. BMJ Open 2020;10:e030501. doi: 10.1136/bmjopen-2019-030501

This article was previously published with missing information in authorship. Please note the below:

Qianyu Zhuang and Liyuan Tao contribute equally to the paper.

